APA (7th ed.) Citation

ZK, M., L, B., JF, S., S, S., EM, W., M, K., & R, W. (2022). Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leukemia & lymphoma, 63(3), 676. https://doi.org/10.1080/10428194.2021.2012664

Chicago Style (17th ed.) Citation

ZK, McQuilten, Busija L, Seymour JF, Stanworth S, Wood EM, Kenealy M, and Weinkove R. "Hemoglobin Is a Key Determinant of Quality of Life Before and During Azacitidine-based Therapy for Myelodysplasia and Low Blast Count Acute Myeloid Leukemia." Leukemia & Lymphoma 63, no. 3 (2022): 676. https://doi.org/10.1080/10428194.2021.2012664.

MLA (9th ed.) Citation

ZK, McQuilten, et al. "Hemoglobin Is a Key Determinant of Quality of Life Before and During Azacitidine-based Therapy for Myelodysplasia and Low Blast Count Acute Myeloid Leukemia." Leukemia & Lymphoma, vol. 63, no. 3, 2022, p. 676, https://doi.org/10.1080/10428194.2021.2012664.